FibroGen FGEN 深 沪
等待开盘 09-18 09:30:00 美东时间
11.14
-0.370
-3.21%
华盛通- 最 高11.8579
- 今 开11.8579
- 成交量 2.52万股
- 最 低 11.14
- 昨 收 11.51
- 总市值 4504.90万
- 52周最高 21.9375
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 4.50
- 委 比 97.29%
- 总股本 404.39万
- 历史最高 1713.75
- 量 比 0.66
- 振 幅 6.24%
- 历史最低 4.50
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
FibroGen announced the successful sale of its China subsidiary to AstraZeneca for approximately $220 million, an increase of $60 million from initial guidance. The transaction includes $85 million in enterprise value and $135 million in net cash. FibroGen also repaid a $81 million term loan to Morgan Stanley Tactical Value, simplifying its capital structure. The sale extends the company's cash runway into 2028. FibroGen plans to initiate a Phase ...
09-02 11:00
Foresight Environmental Infrastructure Updates Share Capital Post-Buyback
Foresight Environmental Infrastructure Limited GBP ( ($GB:FGEN) ) has provided ...
09-01 20:17
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroGen, Inc. will attend the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Thane Wettig will present on September 9 at 12:00 PM ET. The presentation will be live streamed and available for replay on the company's website. FibroGen's management will also be available for one-on-one meetings. The company is focused on developing therapies for anemia and cancer, withroxadustat approved in multi...
08-27 20:02
中国批准将FibroGen中国业务出售给阿斯利康
（来源：欧洲并购与投资） 中国批准将FibroGen中国业务出售给阿斯利康 美国生物制药公司FibroGen（珐博进）已于2月宣布，将其中国子公司出...
08-19 15:35
FibroGen Confirms Regulatory Approval For Sale Of FibroGen International (Hong Kong) Ltd. To AstraZeneca Treasury Limited
Sale of FibroGen China remains on track to close in 3Q 2025
08-18 19:11
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
FibroGen, Inc. announced that the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited has been approved by the China State Administration for Market Regulation. The transaction, initially agreed in February 2025, remains on track to close in the third quarter of 2025, pending other contractual conditions. FibroGen continues to develop innovative therapies for anemia and cancer, including roxadustat and FG-3246.
08-18 11:00
FibroGen Q2 EPS $(1.88) Beats $(2.25) Estimate, Sales $1.35M Miss $2.63M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(2.25) by 16.44 percent. This is a 53 percent increase over losses of $(4.00) per share from the same
08-12 04:22
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Fusion Fuel Signs Non-Binding Letter of Intent to Enter Joint Venture for Specialized Fuel Project in South Africa
Fusion Fuel Green PLC has signed a non-binding Letter of Intent with a South African fuel company to form a joint venture targeting a specialized fuel solution for a project in South Africa. The 51%-owned JV will deploy proprietary boiler technology at a commercial facility, with an expected $248,000 in first-year free cash flow and $1.27 million over five years. Fusion Fuel will invest €480,000 over four months, tied to milestones, and has a rig...
08-11 10:30
Uncovering Potential: FibroGen's Earnings Preview
FibroGen (NASDAQ:FGEN) will release its quarterly earnings report on Monday, 20...
08-09 04:05
